SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients | Zendy

Kosuke Doki | Zendy; Masato Homma | Zendy; Keisuke Kuga | Zendy; Kazutaka Aonuma | Zendy; Yukinao Kohda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients

Author(s) -

Kosuke Doki,

Masato Homma,

Keisuke Kuga,

Kazutaka Aonuma,

Yukinao Kohda

Publication year - 2013

Publication title -

pharmacogenetics and genomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.579

H-Index - 140

eISSN - 1744-6880

pISSN - 1744-6872

DOI - 10.1097/fpc.0b013e328361fb8d

Subject(s) - flecainide , sodium channel blocker , haplotype , mexiletine , qrs complex , medicine , antiarrhythmic agent , pharmacology , cardiology , anesthesia , sodium channel , heart disease , genotype , biology , chemistry , sodium , gene , genetics , organic chemistry , atrial fibrillation

An increased slowing of cardiac conduction induced by sodium channel blockers is remarkably observed in carriers of an Asian-specific promoter haplotype [haplotype B (HapB)] of the cardiac sodium channel gene (SCN5A). We investigated the effect of HapB on the therapeutic range for serum flecainide concentration in Asian patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research